Product Description
Dantrolene is used to help relax certain muscles in your body. It relieves the spasms, cramping, and tightness of muscles caused by certain medical problems such as multiple sclerosis (MS), cerebral palsy, stroke, or injury to the spine. Dantrolene does not cure these problems, but it may allow other treatment, such as physical therapy, to be more helpful in improving your condition. Dantrolene acts directly on the muscles to produce its relaxant effects. Dantrolene is also used to prevent or treat a medical problem called malignant hyperthermia that may occur in some patients during or following surgery or anesthesia. (Sourced from: https://www.mayoclinic.org/drugs-supplements/dantrolene-oral-route/proper-use/drg-20063299?p=1)
Mechanisms of Action: RyR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Czech | Egypt | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Malta | Netherlands | New Zealand | Portugal | Romania | Russia | Slovenia | South Africa | Switzerland | Taiwan | Thailand | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Glabellar Reflex
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FTP-CLIN-01 | P2 |
Unknown Status |
Glabellar Reflex |
2026-01-27 |